


The treatment of lung cancer has undergone a paradigm shift in recent decades with the advent of targeted therapy. The first approval of anti-EGFR targeted therapy in 2013 led to a significant reduction in non-small cell lung cancer (NSCLC) mortality rates. This has spurred the evolution of targeted therapy, with a focus on identifying driver mutations, developing new drugs, and discovering biomarkers. The mechanism of action of targeted therapy is targeting the specific molecular and genetic alterations that drive the proliferation of cancer cells to selectively inhibit their growth. Despite many successful discoveries in lung cancer targeted therapy, challenges remain in overcoming drug resistance, identifying suitable populations, and understanding potential interactions with immunotherapy response.

This book, entitled “*Targeted Therapy in Lung Cancer*,” includes a comprehensive collection of reviews that cover the latest approaches to targeted therapy in lung cancer. In the first section, the identification and clinical implications of driver mutations, the association of mutations with immunotherapy response, and the effect of patient characteristics on targeted therapy response are described. It provides detailed information on the clinical application of targeted therapy in various settings. The second section of the book goes in depth in discussing strategies to target both common (such as *EGFR*, *KRAS*, *TP53*) and rare genetic changes in lung cancer. It covers a broad topic including the biology of these driver alterations in lung cancer and how these alterations shape the drug response.

This book will serve as a comprehensive and up-to-date resource for clinicians, researchers, and students who are interested in targeted therapy for lung cancer. It provides the latest information on targeted therapy, including current challenges and potential solutions. We sincerely hope that this book will contribute to the ongoing efforts to improve the care and outcomes of patients with lung cancer.



R. Stephanie Huang, PhD

*Department of Experimental and Clinical Pharmacology,
College of Pharmacy, University of Minnesota,
Minneapolis, MN, USA*



Yingbo Huang, MS

*Department of Experimental and Clinical Pharmacology,
College of Pharmacy, University of Minnesota,
Minneapolis, MN, USA*